Free Trial

Puma Biotechnology (PBYI) News Today

Puma Biotechnology logo
$3.37 +0.02 (+0.60%)
As of 03:11 PM Eastern

PBYI Latest News

Puma Biotechnology, Inc. stock logo
Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?
Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Above 200-Day Moving Average - What's Next?
Puma Biotechnology, Inc. stock logo
Brian M. Stuglik Sells 8,100 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Brian M. Stuglik sold 8,100 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.39, for a total value of $27,459.00. Following the transaction, the director now owns 94,958 shares in the company, valued at $321,907.62. This trade represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Puma Biotechnology, Inc. stock logo
Insider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 10,800 Shares of Stock
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Troy Edward Wilson sold 10,800 shares of Puma Biotechnology stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $36,720.00. Following the sale, the director now owns 43,550 shares of the company's stock, valued at approximately $148,070. The trade was a 19.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Puma Biotechnology, Inc. stock logo
Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Allison Dorval Sells 11,610 Shares
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Allison Dorval sold 11,610 shares of the business's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $39,474.00. Following the transaction, the director now owns 75,390 shares in the company, valued at approximately $256,326. This represents a 13.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Puma Biotechnology, Inc. stock logo
Alessandra Cesano Sells 12,150 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Alessandra Cesano sold 12,150 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.40, for a total value of $41,310.00. Following the completion of the transaction, the director now directly owns 68,850 shares in the company, valued at $234,090. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Puma Biotechnology, Inc. stock logo
Jay M. Moyes Sells 22,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Jay M. Moyes sold 22,000 shares of the business's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $3.40, for a total value of $74,800.00. Following the completion of the sale, the director now directly owns 53,322 shares in the company, valued at $181,294.80. This trade represents a 29.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Puma Biotechnology, Inc. stock logo
Adrian Senderowicz Sells 27,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Adrian Senderowicz sold 27,000 shares of the company's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $91,800.00. Following the completion of the transaction, the director now owns 27,000 shares in the company, valued at approximately $91,800. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Puma Biotechnology, Inc. stock logo
Two Sigma Investments LP Purchases 131,916 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)
Two Sigma Investments LP lifted its position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 266.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 181,471 shares of the biopharmaceutical company's stock after purchasing an additional 131,916
Puma Biotechnology, Inc. stock logo
78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial Corp
Mackenzie Financial Corp bought a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 78,653 shares of the biopharmaceutical company's stock, valued at approximately $2
Puma Biotechnology, Inc. stock logo
Millennium Management LLC Has $5.78 Million Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)
Millennium Management LLC trimmed its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 34.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,894,126 shares of the biopharmaceutical company's s
Puma Biotechnology, Inc. stock logo
D. E. Shaw & Co. Inc. Buys 165,220 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)
D. E. Shaw & Co. Inc. lifted its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 287.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 222,608 shares of the biopharmaceutical company's stock after purchasing
Puma Biotechnology, Inc. stock logo
Puma Biotechnology (NASDAQ:PBYI) Upgraded to Strong-Buy at Wall Street Zen
Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday.
Puma Biotechnology, Inc. stock logo
Dimensional Fund Advisors LP Has $2.64 Million Stock Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)
Dimensional Fund Advisors LP grew its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 24.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 863,760 shares of the biopharmaceut
Puma Biotechnology, Inc. stock logo
Puma Biotechnology (NASDAQ:PBYI) Raised to "Strong-Buy" at StockNews.com
StockNews.com upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Sunday.
Puma Biotechnology, Inc. stock logo
85,580 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Acquired by Marshall Wace LLP
Marshall Wace LLP bought a new stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 85,580 shares of the biopharmaceutical company's stock, valued at approximate
Puma Biotechnology, Inc. stock logo
Puma Biotechnology (NASDAQ:PBYI) Cut to "Buy" at StockNews.com
StockNews.com cut shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Saturday.
Puma Biotechnology, Inc. stock logo
Zacks Research Issues Pessimistic Forecast for PBYI Earnings
Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Zacks Research cut their Q2 2025 earnings per share estimates for Puma Biotechnology in a report issued on Wednesday, April 30th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.08
Puma Biotechnology, Inc. stock logo
Acorn Capital Advisors LLC Purchases Shares of 2,450,711 Puma Biotechnology, Inc. (NASDAQ:PBYI)
Acorn Capital Advisors LLC acquired a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,450,711 shares of the biopharmaceutical company's stock, valued
Puma Biotechnology, Inc. stock logo
JPMorgan Chase & Co. Increases Stock Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)
JPMorgan Chase & Co. increased its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 182.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 136,897 shares of the biopharmaceutical company's stock after purcha
Puma Biotechnology, Inc. stock logo
Q1 EPS Forecast for Puma Biotechnology Boosted by Analyst
Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Zacks Research increased their Q1 2026 earnings per share (EPS) estimates for Puma Biotechnology in a report released on Wednesday, April 30th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post
Puma Biotechnology, Inc. stock logo
Puma Biotechnology (NASDAQ:PBYI) Upgraded to Strong-Buy at StockNews.com
StockNews.com upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Friday.
Puma Biotechnology, Inc. stock logo
Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday
Puma Biotechnology (NASDAQ:PBYI) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-puma-biotechnology-inc-stock/)
Puma Biotechnology, Inc. stock logo
Eversept Partners LP Decreases Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)
Eversept Partners LP cut its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 23.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 996,102 shares of the biopharmaceutical company's sto
Puma Biotechnology, Inc. stock logo
Puma Biotechnology (NASDAQ:PBYI) Upgraded to "Strong-Buy" at StockNews.com
StockNews.com raised shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Wednesday.
Puma Biotechnology, Inc. stock logo
Kennedy Capital Management LLC Buys 216,329 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)
Kennedy Capital Management LLC boosted its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 36.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 809,375 shares of the biopharmaceutical compan
Puma Biotechnology, Inc. stock logo
WINTON GROUP Ltd Sells 270,739 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)
WINTON GROUP Ltd decreased its position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 87.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,241 shares of the biopharmaceutical company's stock after sell
Puma SE: Undervalued With Tailwinds Ahead
PUMA SE: This Is The Right Time To Buy
Puma Biotechnology, Inc. stock logo
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 32.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 487,368 shares
Puma Biotechnology, Inc. stock logo
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above Two Hundred Day Moving Average - Should You Sell?
Puma Biotechnology, Inc. stock logo
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by StockNews.com
StockNews.com lowered shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Saturday.
Zooming In On Puma Biotechnology's Earnings
Get Puma Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.

PBYI Media Mentions By Week

PBYI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PBYI
News Sentiment

0.36

0.62

Average
Medical
News Sentiment

PBYI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PBYI Articles
This Week

14

2

PBYI Articles
Average Week

Get Puma Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:PBYI) was last updated on 6/24/2025 by MarketBeat.com Staff
From Our Partners